计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 3 篇同行评审文献引用。
Pomalidomide抑制LPS诱导的TNF-alpha释放, IC50为13 nM。
应用:
泊马度胺已被用于:处理BV173 细胞以研究蛋白质水解靶向嵌合体 (PROTAC) 化合物 JQ1-CRBN 在诱导特异性 I 类主要组织相容性复合体 (MHC-I) 肽中的作用 ;用于细胞凋亡研究和细胞内钙分析;作为胎儿血红蛋白 (HbF) 试剂用于研究 对& #946;-地中海贫血/变异血红蛋白 E (HbE) 红系祖细胞中胎儿血红蛋白表达水平与UNC0638 的累加效应。
Information
Pomalidomide (CC-4047) inhibits LPS-inducedTNF-αrelease withIC50of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targetingE3 ligaseand inhibiting theE3 ligase protein cereblon (CRBN). Pomalidomide promotesapoptosisand cell cycle a
In vitro
Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls.
In vivo
Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity.
Cell Data
cell lines:PPC-1 cells
Concentrations:Dissolved in DMSO, final concentrations 2.5-40 μg/mL
Incubation Time:24 or 48 hours
Powder Purity:≥98%
| ALogP | 0.2 |
|---|
H373: 通过长时间或反复暴露对器官造成损害
H360: 可能损害生育力或未出生的孩子
H360Df: 可能会伤害未出生的孩子; 怀疑破坏生育力
H361: 怀疑破坏生育力或未出生的孩子
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P405: 密闭存放
P501: 将内容物/容器处理到。。。
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。
P203: 使用前,获取、阅读并遵守所有安全说明。
P318: 如果暴露或担心,请就医。
P319: 如果你感到不适,请寻求医疗帮助。